- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06293469
Przyspieszone pokrycie płatka w przypadku ciężkiego urazu kończyny dolnej (FLAP ATTACK)
Przyspieszone pokrycie płatów a standardowy czas w leczeniu ciężkich urazów mięśniowo-szkieletowych kończyn dolnych
The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility).
This is the vanguard and international part of the FLAP ATTACK trial.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Infection following severe lower extremity musculoskeletal injuries is a challenging problem. Several factors hypothesized to influence infection have been explored and, in many cases, optimized or found not to be influential. A persistent area of uncertainty and variability is the timing of acute soft tissue coverage. In the United States, the mean time to coverage from injury is 10 days, and infection rates are 20-35%. In the United Kingdom, there are national guidelines to support coverage within 72 hours of injury, and infection rates are less than 10%. While the data to support early coverage is promising, the necessary evidence to make this significant change is lacking. To justify the mobilization of resources and expense required to shift practice, a definitive trial is needed. This trial seeks to fill this critical knowledge gap.
The primary objective of this trial is to determine if accelerated flap coverage (within 72 hours of injury) compared to standard flap coverage timing leads lower rates of infection and infection-related complications. The trial population includes patients 18 years and older with an acute open fracture and/or dislocation below the knee, with a diagnosed need for acute soft tissue coverage with a flap. Patients who undergo primary amputation prior to attempted flap coverage will be excluded. There will be 356 participants randomized in 1:1 ratio to receive either accelerated flap coverage (goal of flap within 72 hours from injury) or flap coverage at the time that reflects the standard of care at each institution. The timing of the trial interventions, other adjunctive treatments, the fracture fixation, and flap coverage procedures will be documented for both treatment groups. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. Participants will have follow-up at 6 weeks, 3 months, 6 months, and 12 months post-randomization.
The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility). The secondary outcomes will independently assess the individual components of the primary outcome at 6 and 12 months, the composite outcome at 12 months, and health-related quality of life and patient satisfaction over 6 and 12 months. An Adjudication Committee will review primary and secondary endpoints and a Data Safety Monitoring Committee (DSMC) will review all safety events.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Lily Mundy, MD
- Numer telefonu: 410-706-2492
- E-mail: LMundy3@jhu.edu
Lokalizacje studiów
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Rekrutacyjny
- The Alfred Hospital
-
Kontakt:
- Lipi Shukla, MBBS, PhD
-
Główny śledczy:
- Lipi Shukla, MBBS, PhD
-
-
-
-
-
Barcelona, Hiszpania, 08035
- Rekrutacyjny
- Vall d'Hebron University Hospital
-
Kontakt:
- Jordi Tomás-Hernández, MD
-
Główny śledczy:
- Antonio Bulla, MD, PhD
-
Główny śledczy:
- Jordi Tomás-Hernández, MD
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1N1
- Rekrutacyjny
- Vancouver General Hospital
-
Kontakt:
- David Stockton, MD
- Numer telefonu: 604-875-4111
- E-mail: david.stockton@vch.ca
-
-
New Brunswick
-
Saint John, New Brunswick, Kanada, E2L 4L2
- Rekrutacyjny
- Saint John Regional Hospital
-
Kontakt:
- Alison Wong, MD
- Numer telefonu: 506-648-6000
- E-mail: alison.wong@dal.ca
-
-
Ontario
-
Toronto, Ontario, Kanada, M4N 3M5
- Rekrutacyjny
- Sunnybrook Health Sciences Centre
-
Kontakt:
- Jana Dengler
- Numer telefonu: 416-480-6100
- E-mail: jana.dengler@sunnybrook.ca
-
-
-
-
California
-
Sacramento, California, Stany Zjednoczone, 95817
- Rekrutacyjny
- UC Davis Medical Center
-
Kontakt:
- Ara A Salibian, MD
-
Główny śledczy:
- Ara A Salibian, MD
-
Główny śledczy:
- Augustine M Saiz, MD
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Rekrutacyjny
- The Johns Hopkins Hospital
-
Kontakt:
- Lily R Mundy, MD
-
Główny śledczy:
- Lily R Mundy, MD
-
Baltimore, Maryland, Stany Zjednoczone, 21224
- Rekrutacyjny
- John Hopkins Bayview Medical Center
-
Kontakt:
- Lily R Mundy, MD
-
Główny śledczy:
- Lily R Mundy, MD
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- Rekrutacyjny
- R Adams Cowley Shock Trauma Center
-
Kontakt:
- Mark J Gage, MD
-
Główny śledczy:
- Mark J Gage, MD
-
Largo, Maryland, Stany Zjednoczone, 20774
- Rekrutacyjny
- University of Maryland Capital Region Medical Center
-
Kontakt:
- Todd Jaeblon, MD
-
Główny śledczy:
- Todd Jaeblon, MD
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
- Rekrutacyjny
- Oregon Health & Science University
-
Kontakt:
- Graham J DeKeyser, MD
-
Główny śledczy:
- Graham J DeKeyser, MD
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Rekrutacyjny
- Vanderbilt University Medical Center
-
Kontakt:
- Lauren M Tatman, MD
-
Główny śledczy:
- Lauren M Tatman, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
The inclusion criteria are:
- Patients 18 years of age or older.
- Severe lower extremity open fracture and/or dislocation below the knee requiring an acute flap for management of the musculoskeletal injury.
- Will have all planned flap surgeries performed by a participating surgeon or delegate.
- Able to be randomized within 48 hours of injury.
The exclusion criteria are:
- Site is unable to implement the accelerated flap protocol due to local logistics.
- Primary amputation anticipated prior to attempted flap for management of the injury.
- Critical limb ischemia that requires re-vascularization for limb perfusion.
- Chronic or acute infection at or near the musculoskeletal injury site at the time of initial injury surgery.
- Burns at the musculoskeletal injury site.
- Incarceration.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Currently enrolled in a trial that does not permit co-enrollment.
- Declined to provide informed consent.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because a legally authorized representative was unavailable.
- Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.
- Prior enrollment in the trial.
- Eligible patient or LAR was not approached within screening window (missed participant).
- Other reason to exclude the patient, as approved by the Principal Investigators.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Accelerated Flap Coverage
Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. |
Timing of the flap surgery is with a goal of 72 hours from injury |
|
Aktywny komparator: Standard of Care Flap Timing
The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. |
Timing of the flap surgery is the standard of care flap timing for the participating institution. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Clinical status
Ramy czasowe: 6 months
|
Clinical status is a hierarchical composite of the following outcomes:
|
6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Mortality
Ramy czasowe: 6 months and 12 months
|
All-cause mortality. Mortality will be time-to-event, with the assumption that earlier is worse than later. |
6 months and 12 months
|
|
Amputation
Ramy czasowe: 6 months and 12 months
|
Amputation related to injury. Amputation will be time-to-event, with the assumption that earlier is worse than later. |
6 months and 12 months
|
|
Unplanned re-operation
Ramy czasowe: 6 months and 12 months
|
Unplanned re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure). Re-operation for infection and major flap complication will account for more than one operation, assuming that more operations are worse. |
6 months and 12 months
|
|
Number of days in hospital
Ramy czasowe: 6 months and 12 months
|
Days in an acute in-patient hospital (i.e., not rehab or nursing facility) |
6 months and 12 months
|
|
Patient-reported health status as assessed by the Euro-QoL (EQ-5D-5L)
Ramy czasowe: 6 months and 12 months
|
Patient-reported health status as assessed by the EQ-5D-5L. The EQ-5D-5L is scored on a 0 to 100 mm scale. 0 mm represents "the worst health you can imagine to 100 mm which represents "the best health you can imagine". |
6 months and 12 months
|
|
Quality of life as assessed by the Limb-Q
Ramy czasowe: 6 months and 12 months
|
Health-related quality of life and patient satisfaction measured with the Limb-Q. The Limb-Q is a set of independently functioning scales. All scales are scored 0-100 (higher = better). The Limb-Q Appearance, Physical, Symptoms, Financial Impact, Life Impact, and Psychological scales will be used. |
6 months and 12 months
|
|
Clinical Status
Ramy czasowe: 12 months
|
Clinical status is a hierarchical composite of the following outcomes: 1. All-cause mortality 2. Amputation related to injury 3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure) 4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility) |
12 months
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Lily Mundy, MD, Johns Hopkins School of Medicine
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- IRB00434587
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .